Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results

BACKGROUND: AGI-101H is an allogeneic gene modified whole cell therapeutic melanoma vaccine, evaluated in over 400 melanoma patients in the adjuvant and therapeutic settings. We present updated long-term survival results from two single-arm, phase II adjuvant trials (Trial 3 and Trial 5) with the fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Mackiewicz, Jacek, Burzykowski, Tomasz, Iżycki, Dariusz, Mackiewicz, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Clinical Trials Monitor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264600/
https://www.ncbi.nlm.nih.gov/pubmed/30486884
http://dx.doi.org/10.1186/s40425-018-0456-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264600/
https://www.ncbi.nlm.nih.gov/pubmed/30486884
http://dx.doi.org/10.1186/s40425-018-0456-1

Ejemplares similares